New combo procedure aims to fix heart rhythm and prevent stroke in one go

NCT ID NCT07450755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a combined procedure in 150 people with atrial fibrillation (AFib) who are at risk for stroke. Doctors will use pulse field ablation to correct the heart's rhythm and then close off a small pouch in the heart (the left atrial appendage) to prevent blood clots. The goal is to see if doing both at once is safe and effective, potentially reducing the need for long-term blood thinners.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pulse field ablation and left atrial appendage closure devices (Farapulse, Watchman Flx)

What this could lead to

If successful, this combined procedure could offer a one-time treatment to control atrial fibrillation and reduce stroke risk, potentially lowering the need for long-term blood thinners.

What could go wrong

This is an early-stage registry with no control group, so results may not prove superiority over standard care. Risks include procedure-related complications like bleeding, stroke, or heart damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Hemorrhage hemorrhagic disease prevention target stroke disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••